CervoMed Positive Results in Phase 2b in Dementia with Lewy Bodies

 A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB)

Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC)

Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase

Company to host investor webcast at 5:00 PM ET Monday to discuss results

Conference Call / Webcast Details

CervoMed will host a conference call and webcast to review and discuss the 16-week results from the Extension phase of the Phase 2b RewinD-LB study today, Monday, March 10, 2025, at 5:00 PM ET. Participants should dial 1-877-425-9470 (domestic) or 1-201-389-0878 (international) with the code 13752218.

To access the Call me™ feature, which avoids having to wait for an operator, click here.

The live webcast and replay will be available under “Events & Presentations” in the Investor Relations section of the Company’s website, https://www.cervomed.com

The results from the extension phase of the RewinD-LB study have been accepted as an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders in Vienna, April 1-5, 2025.

https://www.globenewswire.com/news-release/2025/03/10/3040150/0/en/CervoMed-Announces-Positive-Results-from-the-Extension-Phase-of-its-Phase-2b-Clinical-Study-of-Neflamapimod-in-Patients-with-Dementia-with-Lewy-Bodies.html